Idexx Laboratories price target raised to $620 from $600 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Idexx Laboratories to $620 from $600 and keeps an Overweight rating on the shares. Following “impressive” Q4 upside, the firm views the company’s new FY24 targets as “achievable with an appropriate level of conservatism,” telling investors that the guidance leaves “room for beats/raises for balance of the year.”